| DB ID | MyCo_2908 |
| Title | Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients |
| Year | 2011 |
| PMID | 22170907 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Disease | Aspergillosis (Aspergillus Infection) |
| Associated Medical Condition | Hematological Patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The protocol was approved by the ethics committee of the Saint Louis teaching hospital in Paris, France. |
| Site of Infection | Unspecified |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | A total of 57 patients (4 with proven, 44 with probable, and 9 with possible aspergillosis according to the revised EORTC/MSG [European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group] definitions) were included. |
| Cohort No. | 57 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Sub Technique | ELISA |
| Technique | Immunoassay |
| Analysis Method | FDA Approved -Platelia Aspergillus Ag ELISA |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Marnes la Coquette, France) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
